Streetbeat News

Regulatory

DECAU

Trading halt status for DECAU was updated at 5:45:00 PM ET. The article provides information on the news and resumption times for the stock.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:45 pm

DECA

Trading halt status for DECA was updated at 5:40:00 PM ET. The article provides information on the news and resumption times for the stock.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:40 pm

DECAW

Trading for DECAW was halted at 5:25:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:25 pm

DECAU

Trading for DECAU was halted at 5:25:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:25 pm

DECA

Trading has been halted for DECA at 5:25:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:25 pm

IDEX

Ideanomics has received a notice from Nasdaq regarding listing delinquency. The company is actively working to regain compliance and will provide updates as more information becomes available.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:03 pm

CHX

SLB

SLB and ChampionX have received a second request for additional information from the US Department of Justice regarding their pending transaction. The deal is expected to close in late 2024 or early 2025, pending regulatory approvals. ChampionX stockholders approved the transaction on June 18, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:02 pm

SPB

Spectrum Brands has filed a confidential Form 10 registration statement with the SEC for the spin-off of its Home and Personal Care (HPC) business. The company is exploring various strategic options including a spin-off, sale, or merger.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 8:55 pm

MINM

Minim has received a notification from the Nasdaq Listing Qualifications Department regarding non-compliance with the Stockholders' Equity Requirement. The company plans to regain compliance through a direct equity investment or business combination before the hearing with the Panel, but success is not guaranteed.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 8:49 pm

CARM

NVS

Carisma Therapeutics has terminated its Manufacturing and Supply Agreement with Novartis Pharmaceuticals for its product candidate CT-0508, effective July 31, 2024. The company will focus on its follow-on product candidate CT-0525 and will incur a $4 million termination fee.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 8:47 pm